Kineta, Inc.
๐บ๐ธUnited States
A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
Phase 1
Recruiting
- Conditions
- CancerSolid TumorKidney CancerMelanomaCarcinomaPancreatic CancerColo-rectal CancerGastric CancerEsophageal CancerOvarian Cancer
- Interventions
- Drug: KVA12123 - Dose ExpansionDrug: KVA12123 - Dose Escalation
- First Posted Date
- 2023-02-01
- Last Posted Date
- 2023-07-13
- Lead Sponsor
- Kineta Inc.
- Target Recruit Count
- 314
- Registration Number
- NCT05708950
- Locations
- ๐บ๐ธ
Sarah Cannon Research Institute at Tennessee Oncology, Nashville, Tennessee, United States
๐บ๐ธSarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
๐บ๐ธUCLA Health (Santa Monica Cancer Care), Santa Monica, California, United States
Multiple Ascending Oral Dose 14-Day Trial of LHF-535 in Healthy Participants
- First Posted Date
- 2019-06-21
- Last Posted Date
- 2020-07-09
- Lead Sponsor
- Kineta Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT03993704
- Locations
- ๐ฆ๐บ
Centre for Clinical Studies, Melbourne, Australia
Multiple Ascending Dose Safety Study of ShK-186 (Dalazatide) in Healthy Volunteers
- First Posted Date
- 2015-05-18
- Last Posted Date
- 2015-05-18
- Lead Sponsor
- Kineta Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT02446340
- Locations
- ๐บ๐ธ
PRA International, Lenexa, Kansas, United States
A 4 Week Study of the Safety, Tolerability, and Pharmacodynamics of ShK-186 (Dalazatide) in Active Plaque Psoriasis
- First Posted Date
- 2015-05-06
- Last Posted Date
- 2015-05-06
- Lead Sponsor
- Kineta Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02435342
- Locations
- ๐จ๐ฆ
Innovaderm Research, Inc, Montreal, Quebec, Canada
ยฉ Copyright 2025. All Rights Reserved by MedPath